Hematology最新文献

{"title":"CD7 CAR-T cells eliminate chronic myeloid leukemia stem cells specifically and effectively.","authors":"Wenjing Zhang, Haobing Wang, Ling Tang, Yingjie Kong, Yong You, Xiaojian Zhu, Hongxiang Wang","doi":"10.1080/16078454.2026.2719241","DOIUrl":"https://doi.org/10.1080/16078454.2026.2719241","url":null,"abstract":"<p><strong>Objectives: </strong>Leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) are associated with disease recurrence and progression, cannot be eliminated by tyrosine kinase inhibitors (TKIs), and affect TKI discontinuation in CML patients. Chimeric antigen receptor T cells (CAR-T) therapy can eliminate tumor cells expressing specific antigens. CD7 is highly expressed on LSCs and can distinguish LSCs from normal hematopoietic stem cells (HSCs). This study explored the biological characteristics of CD7, and evaluated the effects of CD7 CAR-T cells on CD7⁺ CML tumor cells and CD7⁺ LSCs in vitro.</p><p><strong>Methods: </strong>We examined CD7 expression in primary CML LSCs, constructed CD7-overexpressing K562 cells, and assessed the in vitro cytotoxicity, degranulation and cytokine secretion of CD7 CAR-T cells against CD7⁺ CML cells and CD34⁺CD7⁺ LSCs, along with the correlation between CD7 and TKI resistance.</p><p><strong>Results: </strong>CD7⁺ CML tumor cells were resistant to TKI to a certain extent. This molecule appears to be relevant to the survival of LSCs in patients with CML receiving TKI-targeted therapy. In the in vitro co-culture system, CD7 CAR-T cells effectively eliminate CD7⁺ CML cells and LSCs and exhibit multiple immunological activities during the co-culture process.</p><p><strong>Discussion: </strong>This study targets the key limitation of current CML treatment in that TKIs fail to eliminate LSCs, and confirms the correlation between CD7 and LSC survival, as well as the targeting potential of CD7 CAR-T for CML.</p><p><strong>Conclusion: </strong>This study showed that using CD7 CAR-T cells to specifically eliminate LSCs is effective and rational in vitro, which provides experimental evidence for LSC-targeted CML therapy and lays a foundation for subsequent in vivo and translational research.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2719241"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and internal validation of a machine learning model for predicting second primary malignancy risk in hodgkin lymphoma survivors: a population-based competing risk analysis.","authors":"Sinian Li, Mingyue Xiong, Zhonggui Gan, Haishan Lu, Yiheng Zhao, Hong Huang, Tingzhuang Yi","doi":"10.1080/16078454.2026.2737562","DOIUrl":"https://doi.org/10.1080/16078454.2026.2737562","url":null,"abstract":"<p><strong>Background: </strong>Hodgkin lymphoma (HL) survivors face an elevated long-term risk of developing second primary malignancies (SPMs), yet accurate prediction tools remain scarce. This study aimed to develop and internally validate a machine learning-based prediction model for SPM risk in HL survivors using a competing risk framework.</p><p><strong>Methods: </strong>We analysed 57,429 patients diagnosed with HL between 2006 and 2020 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were randomly divided into training (<i>n</i> = 40,201, 70%) and internal validation (<i>n</i> = 17,228, 30%) cohorts. A random survival forest (RSF) model was developed to predict SPM occurrence, with death without SPM treated as a competing event. Model performance was compared against the traditional Fine-Grey subdistribution hazard regression. Discrimination was assessed using time-dependent area under the receiver operating characteristic curve (AUC), and calibration was evaluated through calibration plots. Clinical utility was determined via decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) analysis was employed to interpret the model.</p><p><strong>Results: </strong>During follow-up, 4,954 patients (8.6%) developed SPMs, while 9,750 (17.0%) died without SPM. The RSF model demonstrated superior discriminative ability compared to Fine-Grey regression across all time points: AUC at 3 years (0.721 vs. 0.549), 5 years (0.761 vs. 0.555), and 10 years (0.804 vs. 0.553). Calibration plots indicated good agreement between predicted and observed risks. DCA confirmed the RSF model provided greater net clinical benefit across a wide range of threshold probabilities. SHAP analysis identified age as the most influential predictor, followed by disease stage, radiotherapy status, race, sex, and chemotherapy.</p><p><strong>Conclusions: </strong>The RSF-based machine learning model accurately predicts SPM risk in HL survivors within a competing risk framework, substantially outperforming traditional regression approaches. This interpretable prediction tool may facilitate personalised surveillance strategies and risk-adapted follow-up for HL survivors.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2737562"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between household pesticide exposure and anemia is modified by dietary selenium intake: a population-based study.","authors":"Jinhui Gan, Qing Xie, Xiaoqin Xin","doi":"10.1080/16078454.2026.2659975","DOIUrl":"10.1080/16078454.2026.2659975","url":null,"abstract":"<p><strong>Background: </strong>While the detrimental health effects of occupational pesticide exposure are well-documented, the association between household pesticide use and anemia in the general adult population remains underexplored. Furthermore, the potential for dietary factors, such as selenium, to modulate this relationship is unknown.</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis using data from 14,708 adults (≥18 years) who participated in the National Health and Nutrition Examination Survey (NHANES) from 2013 to 2018. Household pesticide exposure was self-reported. Anemia was defined according to World Health Organization criteria (hemoglobin <13 g/dL for men, <12 g/dL for women). Dietary selenium intake was categorized as low (<125 µg/day) or high (≥125 µg/day). Multivariable logistic regression models were used to evaluate the association between pesticide exposure and anemia. The modifying effect of selenium was assessed using an interaction term and stratified analyses.</p><p><strong>Results: </strong>Of the 14,447 participants included in the final analysis, 1,516 (10.5%) reported household pesticide exposure, and 1,506 (10.4%) met the criteria for anemia. Household pesticide exposure was associated with higher odds of anemia (OR = 1.23; 95% CI: 1.03-1.47). A significant interaction with selenium intake was observed (<i>p</i> = 0.032). Among participants with low selenium intake, pesticide exposure increased anemia risk (OR = 1.31; 95% CI: 1.06-1.61), whereas no association was found in the high selenium group (OR = 0.74; 95% CI: 0.49-1.11).</p><p><strong>Conclusion: </strong>This study provides novel evidence that household pesticide exposure is associated with a modestly increased prevalence of anemia in the general U.S. adult population. Furthermore, our findings suggest that adequate dietary selenium intake may mitigate this hematological risk.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2659975"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First report of a rare hemoglobin variant in the Chinese population: clinical and hematological characteristics of Hb Norton [HBA2:c.217C>G] and its impact on HbA1c testing: a case report.","authors":"Jian Shang, Zirui Cao, Weidong Chen, Huijun Yang","doi":"10.1080/16078454.2026.2665490","DOIUrl":"10.1080/16078454.2026.2665490","url":null,"abstract":"<p><strong>Objectives: </strong>Hemoglobin (Hb) variants are a common type of single-gene disorder and a frequent source of interference in HbA_1c testing. Here, we first report a rare Hb variant, Hb Norton [HBA2:c.217C>G], in the Chinese population.</p><p><strong>Methods and results: </strong>A 38-year-old man presented with a normal clinical and hematological phenotype. He was suspected of carrying an Hb variant following an HbA_1c measurement using a high-performance liquid chromatography (HPLC) method (Bio-Rad D100), which resulted in an extremely high value of 20.24%. HbA_1c was reanalyzed using a capillary electrophoresis (CE) method (Capillarys3 TERA) and a boronate affinity HPLC system (Premier Hb9210), and the results were 5.49% and 5.60%, respectively. Hemoglobin analysis by CE and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) revealed a variant peak with a mass-to-charge ratio (m/z) = 10105 Da. Sanger sequencing confirmed the presence of a rare Hb variant, Hb Norton [HBA2:c.217C>G]. It was conclusively confirmed that the co-elution of Hb Norton and HbA_1c components led to the falsely elevated HbA_1c values.</p><p><strong>Conclusions: </strong>Some rare variants can severely affect HbA_1c analysis. When encountering abnormally high values that are difficult to explain, one should consider whether variant interference is present.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2665490"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune reconstitution and viral reactivation after allogeneic hematopoietic stem cell transplantation in hematologic malignancies.","authors":"Muhammad Qaiser, Hao Zhou, Guangyu Zhou, Guilin Ren, Xi Dou, Xin Wang, Xiaoqiong Tang, Xiaohua Luo, Hongbin Zhang, Asad Nawaz, Jianbin Chen, Lin Liu, Muhammad Junaid Akram, Li Wang","doi":"10.1080/16078454.2026.2707676","DOIUrl":"10.1080/16078454.2026.2707676","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate associations between post-transplant immune reconstitution, Epstein-Barr virus (EBV) and cytomegalovirus (CMV) DNAemia/reactivation, and survival after allogeneic hematopoietic stem cell transplantation (HSCT).</p><p><strong>Methods: </strong>We conducted a retrospective observational cohort study of 312 patients with hematologic malignancies who underwent allogeneic HSCT between 2016 and 2024. Bone marrow B-cell proportion and peripheral blood lymphocyte subsets were assessed longitudinally by flow cytometry. EBV and CMV reactivation was monitored by quantitative PCR and analyzed as surveillance-defined reactivation status. Landmark-based logistic regression evaluated associations between immune-reconstitution parameters and viral reactivation; receiver operating characteristic analysis assessed model discrimination, and Cox regression evaluated overall survival determinants.</p><p><strong>Results: </strong>CMV and EBV DNAemia/reactivation occurred in 42.0% and 31.4% of patients, respectively, and were significantly correlated (<i>ρ</i> = 0.191, <i>p</i> = 0.028). Higher bone marrow B-cell proportion at sixmonths was associated with lower odds of CMV DNAemia/reactivation (OR = 0.947, 95% CI: 0.901-0.995, <i>p</i> = 0.034). For EBV, an exploratory interaction between 12-month CD8⁺ T-cell recovery and chronic GVHD was associated with EBV DNAemia/reactivation status (<i>p</i> = 0.039). Lower NK-cell levels were observed in patients with EBV and CMV coinfection (<i>p</i> = 0.021 and <i>p</i> = 0.036, respectively). Overall survival was mainly associated with relapse (HR = 5.5, <i>p</i>0.001) and conditioning regimen, whereas viral reactivation was not significantly associated with survival.</p><p><strong>Discussion: </strong>Intermediate immune-reconstitution landmarks showed distinct associations with surveillance-defined viral reactivation, particularly six-month B-cell proportion for CMV and CD8⁺ T-cell recovery in the context of chronic GVHD for EBV.</p><p><strong>Conclusion: </strong>Longitudinal immune-reconstitution patterns may help characterize persistent post-HSCT immune vulnerability, although prospective studies incorporating viral timing and treatment-exposure data are needed for validation.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2707676"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and genetic features of Ph-negative myeloproliferative neoplasms with dual-driver gene positivity.","authors":"Yan Yang, Qunyi Guo, Tao-Hsin Tung, Jia Zhang, Yuanwen Wang, Shuangwei Ying","doi":"10.1080/16078454.2026.2717810","DOIUrl":"https://doi.org/10.1080/16078454.2026.2717810","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the clinical laboratory characteristics and gene mutation features of dual-driver gene positivity in patients with Philadelphia chromosome-negative myeloproliferative neoplasm (Ph-negative MPN).</p><p><strong>Methods: </strong>We conducted a retrospective analysis of clinical data and genetic test results from 203 newly diagnosed patients with Ph-negative MPN. Of these, 194 had single-driver gene positivity and 9 had dual-driver gene positivity. High-throughput sequencing was used to detect mutations in <i>JAK2</i>, <i>CALR</i>, and <i>MPL</i>. Clinical characteristics and gene mutation profiles were compared between the two patient groups.</p><p><strong>Results: </strong>The incidence of dual-driver gene positivity was 4.4% (9/203), with the most common combinations being <i>JAK2</i> with <i>CALR</i> (4 patients) and <i>JAK2</i> with <i>MPL</i> (4 patients). Compared with the single-driver group, the dual-driver group had a significantly higher risk of bleeding [4.1% (8/194) vs. 33.3% (3/9), <i>P</i> = 0.008] and a higher proportion of uncommon mutations [3.6% (7/194) vs. 33.3% (3/9), <i>P</i> = 0.006]. No statistically significant differences were observed between the two groups regarding age, thrombosis incidence, splenomegaly, or routine blood test indicators. During follow-up, 1 patient in the dual-driver group died from cerebrovascular disease. No leukaemia transformation or disease-related deaths occurred among the remaining patients.</p><p><strong>Discussion: </strong>The increased bleeding risk in dual-driver patients may be related to a higher proportion of <i>CALR</i> mutations, elevated platelet counts, and higher variant allele frequencies, though these findings require validation in larger cohorts due to the small sample size. The higher prevalence of uncommon mutations suggests a more complex mutational landscape in this subgroup.</p><p><strong>Conclusion: </strong>Patients with Ph-negative MPN and dual-driver gene positivity may have a higher risk of bleeding and a more complex gene mutation profile.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2717810"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miR-877-5P acts as a tumor suppressor in multiple myeloma by targeting MAPK8: a study on prognostic value and functional mechanism.","authors":"Zhimin Bai, Qiulian Luo, Shasha Zhao","doi":"10.1080/16078454.2026.2722564","DOIUrl":"https://doi.org/10.1080/16078454.2026.2722564","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate Investigate the expression level, prognostic value, and biological function of miR-877-5p in MM.</p><p><strong>Methods: </strong>A total of 103 MM patients and 98 non-tumor controls were included in the study. miR-877-5p expression level was verified by RT-qPCR, and its prognostic value was evaluated through Kaplan-Meier and the Cox regression model. MM cell proliferation and apoptosis were assessed with the CCK‑8 assay and flow cytometry. The potential target genes of miR-877-5p were predicted by bioinformatics analysis and verified by dual luciferase assay. Rescue assays confirmed that MAPK8 mediates the regulatory function of miR-877-5p.</p><p><strong>Results: </strong>miR-877-5p was reduced in MM, and its low level was associated with a poorer overall survival of patients, being an independent prognosticator of poor survival in MM. Function experiments confirmed that overexpression of miR-877-5p could inhibit the proliferation of MM cells and promote apoptosis. Mechanistically, MAPK8 was a direct downstream target of miR-877-5p. MAPK8 was upregulated in MM and negatively correlated with miR-877-5p levels. Rescue assays were conducted to verify that MAPK8 overexpression reversed the effect of miR-877-5p on MM cell proliferation and apoptosis.</p><p><strong>Discussion: </strong>These findings indicate that miR-877-5p exerts tumor-suppressive functions in MM, likely through negative regulation of MAPK8. The miR-877-5p/MAPK8 axis may represent a novel regulatory pathway involved in MM progression.</p><p><strong>Conclusions: </strong>miR-877-5p acts as a tumor suppressor in MM and may serve as a potential biomarker for prognosis assessment. Its regulatory role in MM progression is likely mediated through targeting and inhibiting MAPK8.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2722564"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.","authors":"Xiaomei Wan, Zhong Yu, Chengcheng Huang, Ying Ren","doi":"10.1080/16078454.2026.2691533","DOIUrl":"https://doi.org/10.1080/16078454.2026.2691533","url":null,"abstract":"<p><strong>Objective: </strong>Acute myeloid leukemia (AML) is a severe and life-threatening malignant disease of the hematopoietic system. Our previous research found that ANP32B is regulated by super enhancers in pediatric AML and regulates the progression of AML by modulating histone H3K27ac. Using virtual screening technology, we discovered that Raloxifene may be a small-molecule inhibitor targeting ANP32B.</p><p><strong>Methods: </strong>Proliferation and apoptosis analysis were used to evaluate the effect of Raloxifene on AML cells. By establishing a xenograft model in NSG mice, 10.0 mg/kg of Raloxifene or a control solvent was intraperitoneally injected into the mice daily, and the tumor progression was monitored. Additionally, RNA sequencing, qRT‒PCR and WB were used to measure gene expression levels after Raloxifene treatment.</p><p><strong>Results: </strong>The CCK-8 assay showed the IC50 value of Raloxifene in AML cells. The number and size of colony-forming AML cells treated with Raloxifene significantly decreased, and cell apoptosis increased in a dose-dependent manner. The fluorescence values in NSG mice treated with Raloxifene was significantly lower than control group. RNA sequencing revealed that Raloxifene inhibited the expression of the MYC pathway genes in MV4-11 cells.</p><p><strong>Conclusion: </strong>Raloxifene exhibits anti-AML activity both in vitro and in vivo. By targeting ANP32B, Raloxifene effectively inhibits the proliferation of AML cells, induces cell apoptosis, and reduces the expression of C-MYC. Raloxifene may potentially serve as a candidate drug for the treatment of acute myeloid leukemia.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2691533"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life among older adults undergoing hematopoietic stem cell transplantation: a narrative review.","authors":"Xiao-Lin Liu, Xin-Xin He, Mei-Jiao Li, Mei Guo, Dan Li, Xiao-Dong Xu","doi":"10.1080/16078454.2026.2659974","DOIUrl":"10.1080/16078454.2026.2659974","url":null,"abstract":"<p><strong>Introduction: </strong>With the global aging population and the expanded application of hematopoietic stem cell transplantation (HSCT) in older adults, understanding quality of life (QOL) outcomes in this vulnerable group is of paramount importance.</p><p><strong>Objectives: </strong>This narrative review synthesizes current evidence to (1) describe the trajectory of QOL in older HSCT recipients; (2) identify the key transplant-related, physiological, and psychosocial determinants of post-transplant well-being; and (3) evaluate existing and emerging strategies to improve patient outcomes.</p><p><strong>Methods: </strong>A literature search was conducted in PubMed/MEDLINE, Web of Science, and Embase (inception to December 2024) using terms related to HSCT, older adults, and QOL. Articles focusing on patients aged ≥60 years were selected to synthesize evidence on QOL outcomes, influencing factors, and interventions.</p><p><strong>Results: </strong>Older adults experience significant QOL decline, typically nadiring within three months post-transplant, with infrequent full recovery to baseline. Key determinants include transplant modality (allogeneic vs. autologous), regimen intensity, and complications like graft-versus-host disease. These interact with patient-specific factors such as frailty, nutritional status, psychological distress, and social support. Emerging multidisciplinary strategies, including optimized conditioning regimens, structured psychosocial support, and geriatric assessment-informed enhanced recovery programs, show promise in mitigating QOL impairment.</p><p><strong>Discussion: </strong>The evidence highlights the multifactorial nature of QOL in this population. A critical gap remains the lack of standardized, HSCT-specific geriatric assessment tools to guide personalized interventions. While multidisciplinary care is advocated, its components require further refinement and validation for older adults.</p><p><strong>Conclusion: </strong>A holistic, patient-centered approach integrating geriatric principles is essential to improve long-term survivorship and QOL in the growing population of older adults undergoing HSCT.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2659974"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probable sarcopenia and bone health in transfusion-dependent beta thalassemia patients.","authors":"Sevil Sadri, Nazif Yalcin, Serkan Guven, Aysegul Ertinmaz, Nizameddin Koca, Vildan Gursoy","doi":"10.1080/16078454.2026.2712127","DOIUrl":"https://doi.org/10.1080/16078454.2026.2712127","url":null,"abstract":"<p><strong>Objectives: </strong>Low bone mass    is common in adults with transfusion-dependent thalassemia (TDT). While sarcopenia contributes to frailty, studies examining its association with falls and fractures in TDT remain limited. This study aimed to determine the prevalence of probable sarcopenia in adults with transfusion-dependent thalassemia and to identify related risk factors.</p><p><strong>Methods: </strong>This cross-sectional study included 45 adult TDT patients followed at Bursa City Hospital Hematology Clinic between September 2023 and September 2024, and 40 age- and sex-matched healthy controls. Bone mineral density (BMD) was assessed per Turkish Endocrinology Osteoporosis Guidelines and classified as normal, osteopenia, or osteoporosis. Probable sarcopenia was evaluated according to EWGSOP2 criteria based on handgrip strength measurements[14]. Anthropometric data and biochemical parameters were recorded.</p><p><strong>Results: </strong>Eighty-five participants (52.9% TDT, 47.1% controls) were evaluated. The mean BMI was 21.6 ± 1.99 kg/m². No significant differences were observed in calcium, vitamin D levels (<i>p</i> = 0.492, <i>p</i> = 0.068, <i>p</i> = 0.911, respectively).     Handgrip strength was significantly lower in TDT patients (24.96 ± 12.75 kg) than in controls (33.9 ± 15.39kg; <i>p</i> = 0.004). Probable sarcopenia was identified in 13.3% of patients and in none of the controls (<i>p</i> = 0.027).</p><p><strong>Discussion: </strong>Routine screening for probable sarcopenia should be incorporated into fracture prevention strategies for TDT, particularly among osteoporotic individuals. Therefore, the findings of this study should be interpreted as exploratory observations rather than confirmatory evidence.</p><p><strong>Conclusion: </strong>Probable sarcopenia was identified in a subset of adult patients with TDT based on reduced handgrip strength according to EWGSOP2 criteria. Future longitudinal and multicenter studies incorporating muscle mass and functional performance measurements are required to confirm these findings.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2712127"},"PeriodicalIF":2.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}